---
title: "BGNE.US (BGNE.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BGNE.US/news.md"
symbol: "BGNE.US"
name: "BGNE.US"
parent: "https://longbridge.com/en/quote/BGNE.US.md"
datetime: "2026-05-21T05:25:11.469Z"
locales:
  - [en](https://longbridge.com/en/quote/BGNE.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BGNE.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BGNE.US/news.md)
---

# BGNE.US (BGNE.US) — Related News

### [Beigene is repriced: Innovative drug companies begin to deliver cash flow results](https://longbridge.com/en/news/286864188.md)
*2026-05-19T06:18:25.000Z*
> Beigene's Q1 2026 financial report shows global total revenue of USD 1.513 billion, a year-on-year increase of 35.5%; GA

### [Beigene's new drug has been approved for market launch in the U.S.! Hong Kong pharmaceutical stocks have corrected for 3 consecutive days, and the overall pharmaceutical sector is experiencing "stagnant growth"? The Hong Kong Stock Connect innovative drug ETF, Huatai-PineBridge, fell over 2%, with funds net inflowing for 4 consecutive days](https://longbridge.com/en/news/286419889.md)
*2026-05-14T10:39:11.000Z*
> Beigene's innovative drug BCL-2 inhibitor Baiyueda® has received accelerated approval from the FDA in the United States 

### [BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma](https://longbridge.com/en/news/286330888.md)
*2026-05-13T23:37:16.000Z*
> BeOne Medicines Ltd has received accelerated U.S. FDA approval for BEQALZI (sonrotoclax), the first BCL2 inhibitor for a

### [Beigene: Baeyunda® has been approved by the U.S. FDA as the first and currently only BCL2 inhibitor for the treatment of relapsed/refractory mantle cell lymphoma in the United States](https://longbridge.com/en/news/286330824.md)
*2026-05-13T23:49:07.000Z*
> Beigene announced that its next-generation BCL2 inhibitor Baiyueda® (Sotoclar, BEQALZI™) has received accelerated approv

### [Growing Attention on Machinery Equipment and Pharmaceutical Sectors: Institutions Uncover Structural Opportunities in May Surveys](https://longbridge.com/en/news/286325855.md)
*2026-05-13T22:34:12.000Z*
> Since May, over 1,700 listed companies have hosted Institutional Investor surveys, with the machinery equipment industry

### [Domestic new drugs are selling explosively overseas](https://longbridge.com/en/news/286069475.md)
*2026-05-12T09:07:59.000Z*
> Domestic innovative drugs have performed excellently in overseas markets, with sales of Zebutini expected to reach USD 3

### [UBS Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)](https://longbridge.com/en/news/285800046.md)
*2026-05-09T06:47:23.000Z*
> UBS Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)

### [From Loss to Profit, Domestic Innovative Drugs Will Say Goodbye to "Burning Money Without Making Money"?](https://longbridge.com/en/news/285574163.md)
*2026-05-07T14:38:17.000Z*
> With the disclosure of the 2025 annual reports, domestic innovative drug companies have achieved profitability, breaking

### [Beigene Q1 net profit turns profitable, over 70% of revenue relies on a single major product, growth rate significantly slows down](https://longbridge.com/en/news/285488795.md)
*2026-05-07T05:27:19.000Z*
> Beigene achieved revenue of 10.544 billion yuan in the first quarter of 2026, a year-on-year increase of 31.0%, with a n